GLP1R and myocardial infarction: The main objective of the study was to describe the prevalence of GLP-1 receptor agonist use and to provide baseline, pre-uptake, population-level estimates of major adverse cardiovascular events (myocardial infarction, stroke, or cardiovascular death) and mortality among obese US adults without diabetes using pooled NHANES data from 2011 to 2018.